- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03508297
Reflectance Confocal Microscopy to Diagnose MM & LM
Reflectance Confocal Microscopy to Diagnose Malignant Melanoma and Lentigo Maligna
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Design This is an observational, non-randomised, non-controlled, prospective cohort study to look at the efficacy of in vivo RCM as a diagnostic tool in the diagnosis of MM and LM.
Study Endpoints The hypothesis of this study is that the use of RCM is would reduce the NNE prior to definitive treatment by at least 30% from the current value of approximately 10.
The secondary hypothesis is that the intra- & inter-observer agreement for interpreting the RCM images will have kappa scores 0.6 or greater (indicating good agreement).
Setting and recruitment Patients will be recruited from the outpatient clinics of the Skin Care Network Barnet, and from the outpatient clinics of the Chase Farm and Barnet sites of Royal Free Hospital NHS Foundation Trust.
Participants The number of true negative lesions examined in this study will be 654. It is anticipated that this will result in a total of 661 lesions being recruited. 10% of participants are expected to have more than one lesion sampled.
The result of biopsy for each lesion will not be known until after the lesion has been included in the study. Therefore lesions will be added to the study until the required number of true negatives has been included.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, EN5 4QS
- Skin Care Network Barnet Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18 years or older
- Patient with a pigmented lesion recommended for excision because of suspicion of MM or LM.
- Patient willing and able to give informed consent
Exclusion Criteria:
- Recurrent MM or LM
- Patient on immunosuppresants
- Patient with significant co-morbidity or skin disease
- Patient not suitable for diagnostic biopsy
- Location of lesion unsuitable, inaccessible or impractical for scanning with RCM as determined by investigator
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number Needed to Excise
Time Frame: During exam (biopsy results typically available within one week).
|
The number of suspicious lesions (defined by conventional histology) biopsied to find one cancerous lesion
|
During exam (biopsy results typically available within one week).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
intra- & inter-observer agreement for interpreting the RCM images will have kappa scores 0.6 or greater
Time Frame: 6 months
|
A measure of how consistently readers can diagnose from confocal images.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Howard Stevens, MA PhD, Skin Care Network Ltd.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS-MAV-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.